[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"attr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:attr":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100551878","non-interventional-study-of-patients-with-transthyretin-attr-amyloidosis-100551878",false,"NCT06465810","Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis","A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis","MaesTTRo","Inclusion Criteria:\n\n* Patient willing and able to provide written informed consent to participate in the study\n* Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis\n* Aged ≥18 years at the time of signing the informed consent\n* Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)\n\nExclusion Criteria:\n\n* Concurrent participation in any interventional trial for ATTR amyloidosis\n* Involvement in the planning and\u002For conduct of the current study\n* Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)\n* Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers","ALL","18 Years","130 Years",{"count":21,"type":22},1850,"ESTIMATED","OBSERVATIONAL","The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.",[26,27,28,29,30,31],"Transthyretin Amyloidosis","ATTR-CM","ATTRv-PN","ATTR","ATTR-Mixed","hATTR",[33,34,35,36,37,38,39,40,41,42,43,29,44,45,46,47,48,49,50,51,52,53],"Amyloidosis","Transthyretin","Hereditary transthyretin-mediated (hATTR) amyloidosis","hATTR amyloidosis","Hereditary ATTR amyloidosis","Wild-type amyloidosis","wtATTR amyloidosis","ATTRv amyloidosis","ATTRwt amyloidosis","Polyneuropathy","Familial amyloid polyneuropathies","Transthyretin amyloidosis","TTR-mediated amyloidosis","Polyneuropathies","Amyloid neuropathies","Amyloid neuropathies, familial","Amyloidosis, familial","Eplontersen","Non-interventional","Observational","Real-world","RECRUITING","2026-06-19",{"date":57,"type":58},"2026-06-23","ACTUAL",{"date":60,"type":58},"2024-06-25",{"date":62,"type":22},"2031-12-29",{"name":64,"class":65},"AstraZeneca","INDUSTRY",74,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":17,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":104},"100638540","petct-imaging-in-carriers-of-ttr-mutations-100638540","NCT07591038","PET\u002FCT Imaging in Carriers of TTR Mutations","Iodine-124 Evuzamitide PET\u002FCT Imaging in Carriers of TTR Mutations","EPIC-TTR","A. Pathogenic TTR Allele Carriers without HF\n\nInclusion:\n\n* men and women ages 30-80 who are pathogenic allele TTR carriers without history of HF (this will be assessed by study personnel and defined as : 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)\n* have already completed the protocol for NCT05489549 at UT Southwestern only\n\nExclusion:\n\n* a self-reported history or clinical history of HF\n* other known causes of cardiomyopathy\n* history of light-chain cardiac amyloidosis\n* prior type 1 myocardial infarction\n* cardiac transplantation\n* liver transplantation\n* body weight or habitus that exceeds the site-specific PET\u002FCT parameters\n* estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* inability to safely undergo PET\u002FCT\n* participating in a clinical trial for ATTR treatments or taking a fibril deleting agent\n* pregnancy or breastfeeding\n* patients taking heparin or heparin derivatives for anticoagulation\n* allergy to potassium iodide\n* known uncorrected thyroid disorder\n\nB. Subjects with symptomatic hATTR-CA (may be supplemented with other ATTR-CA genotypes including wild-type in the occasion of slow enrollment):\n\nInclusion:\n\n* men and women ages 30-80 who have symptomatic V122I hATTR-CA as determined by a history of HF (this will be assessed by study personnel and defined as : 1) history of hospitalization within the previous 12 months for management of HF; 2) an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)\n* hATTR-CA previously diagnosed histologically by amyloid staining and tissue typing with immunohistochemistry or mass spectrometry or by bone scintigraphy in without abnormal M-protein\n* TTR gene sequencing confirming the TTR variant\n* have already completed the protocol for NCT05489549 at UT Southwestern only\n\nExclusion:\n\n* other known causes of cardiomyopathy\n* history of light-chain cardiac amyloidosis\n* cardiac transplantation\n* liver transplantation\n* history of type I myocardial infarction\n* body weight or habitus that exceeds the site-specific PET\u002FCT parameters\n* estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* inability to safely undergo PET\u002FCT\n* participating in a clinical trial for ATTR treatments or taking a fibril deleting agent\n* patients taking heparin or heparin derivatives for anticoagulation\n* pregnancy or breastfeeding\n* allergy to potassium iodide\n* known uncorrected thyroid disorder\n\nC. Non-carrier race-matched controls:\n\nInclusion:\n\n* men and women ages 30-80 who are non-carriers without history of HF (this will be assessed by study personnel and defined as: 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or 3) No clinical diagnosis of HF from a treating clinician\n* have previously enrolled in the Dallas Heart Study\n\nExclusion:\n\n* a self-reported history or clinical history of HF\n* other known causes of cardiomyopathy\n* history of light-chain cardiac amyloidosis\n* prior type 1 myocardial infarction\n* cardiac transplantation\n* liver transplantation\n* body weight or habitus that exceeds the site-specific PET\u002FCT parameters\n* estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* inability to safely undergo PET\u002FCT\n* participating in a clinical trial for ATTR treatments or taking a fibril deleting agent\n* patients taking heparin or heparin derivatives for anticoagulation\n* pregnancy or breastfeeding\n* allergy to potassium iodide\n* known uncorrected thyroid disorder",true,"30 Years","80 Years",{"count":79,"type":22},80,"The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using a new radiotracer dye (iodine-124 evuzamitide, I-124E).\n\nParticipants will undergo a screening that includes a medical history review and completion of quality-of-life surveys. Once screening is complete, participants will undergo an imaging test called a positron emission tomography (PET) scan combined with computed tomography (PET\u002FCT) to make images of the body. The new radiotracer dye (I-124E, a radioactive contrast) will be used during the PET\u002FCT to make amyloidosis visible in the heart and body.",[29,82,83,84],"ATTR Gene Mutation","Cardiomyopathy","Transthyretin Mediated Amyloidosis (ATTR)",[86,87,88,89,90,91,29,92],"transthyretin","amyloidosis","carriers of abnormal gene","TTR","PET\u002FCT","evuzamitide","TTR gene","NOT_YET_RECRUITING","2026-05-15",{"date":96,"type":58},"2026-05-19",{"date":98,"type":22},"2026-08-01",{"date":100,"type":22},"2030-06-30",{"name":102,"class":103},"University of Texas Southwestern Medical Center","OTHER",1]